- Moody's•yesterdayAstellas Pharma Inc. -- Moody's: Japanese pharmaceutical companies' expiring drugs patents could prompt strategic alliances
Tokyo, October 20, 2016-- Moody's Japan K.K. says that the expiry of key drug patents over the next 1-3 years will pressure the revenues of the rated Japanese pharmaceutical companies, and could prompt ...
- PR Newswire•4 days agoTakeda Presents Real-World Vedolizumab Data in Ulcerative Colitis and Crohn's Disease at 2016 American College of Gastroenterology (ACG) Annual Scientific Meeting
DEERFIELD, Ill., Oct. 17, 2016 /PRNewswire/ -- Today, Takeda Pharmaceuticals U.S.A., Inc. ("Takeda"), announced data highlighting the effectiveness and safety profile of vedolizumab for the treatment ...
- PR Newswire•4 days agoTakeda's Vedolizumab Demonstrated Robust Clinical Effectiveness and Safety in Inflammatory Bowel Disease in More Than 50 Real-World Studies
OSAKA, Japan, Oct. 17, 2016 /PRNewswire/ -- Takeda Pharmaceutical Company Limited [TSE: 4502], ("Takeda") is presenting data on the real-world effectiveness and safety of vedolizumab in patients with moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD) during the United European Gastroenterology (UEG) Week in Vienna, Austria, October 16 to 19, 2016. Findings indicated notable clinical remission rates, reductions in disease activity scores and improved mucosal healing in more than 5,000 patients with UC and CD receiving treatment with vedolizumab in real-world clinical practice. A systematic review identified 51 reports of real-world studies of vedolizumab.
Takeda Pharmaceutical Company Limited (TKPYY)
Other OTC - Other OTC Delayed Price. Currency in USD
|Day's Range||0.00 - 0.00|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||24.49|
|Avg Vol (3m)||32,833|
|Dividend & Yield||0.87 (3.76%)|